Loading...
Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma
Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter symptomatic progression. To improve outcomes, several phase I-II trials are currently examining SOR with radiation (RT) for...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Public Library of Science
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3675179/ https://ncbi.nlm.nih.gov/pubmed/23762417 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0065726 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|